专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20120089232A1 MEDICAL DEVICES WITH GALVANIC PARTICULATES 审中-公开
标题翻译：具有气雾颗粒的医疗装置
公开(公告)号：US20120089232A1
公开(公告)日：2012-04-12
申请号：US13207398
申请日：2011-08-10
申请人： Jennifer Hagyoung Kang Choi , Chunlin Yang , Ying Sun , Carrie H. Fang , James E. Hauschild , Abla A. Creasey
发明人： Jennifer Hagyoung Kang Choi , Chunlin Yang , Ying Sun , Carrie H. Fang , James E. Hauschild , Abla A. Creasey
IPC分类号： A61F2/30 , H01B1/20 , H01B1/00 , H01B1/02 , B82Y30/00
CPC分类号： A61K9/143 , A61K33/06 , A61K33/30 , A61K33/34 , A61K33/38 , A61L15/18 , A61L15/42 , A61L26/0004 , A61L26/0066 , A61L27/24 , A61L27/30 , A61L27/306 , A61L27/50 , A61L27/54 , A61L29/106 , A61L29/14 , A61L31/088 , A61L31/14 , A61L2300/102 , A61L2300/104 , A61L2300/402 , A61L2300/404 , A61L2300/41 , A61L2300/414 , A61L2300/45 , A61L2300/622
摘要： Implantable medical devices having galvanic particulates are disclosed. The particulates may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The present invention further provides a combination of galvanic particulates with an aqueous gel, a method of making this combination, and a method of treatment using this combination. The devices and compositions may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, tissue regeneration promoting, and pain reduction or elimination.
摘要翻译：公开了具有电偶颗粒的可植入医疗装置。颗粒可以涂覆在医疗装置的表面的至少一部分上。此外，电化学颗粒可以包含在用于制造抗微生物医疗装置的材料中，或者可以嵌入医疗装置的表面中。本发明还提供了新的涂布方法和加工方法。本发明还提供电偶粒子与水性凝胶的组合，制造该组合的方法以及使用该组合的治疗方法。所述装置和组合物可以具有有利的特征和效果，包括抗微生物，抗炎，组织再生促进和疼痛减轻或消除。

62. 发明申请

US20120052894A1 METHODS AND APPARATUS FOR PARALLEL SCHEDULING OF FREQUENCY RESOURCES FOR COMMUNICATION NODES 有权
标题翻译：用于通信节点频率资源并行调度的方法和装置
公开(公告)号：US20120052894A1
公开(公告)日：2012-03-01
申请号：US12869317
申请日：2010-08-26
申请人： Jawad Manssour , Christian Skärby , Ying Sun
发明人： Jawad Manssour , Christian Skärby , Ying Sun
IPC分类号： H04B7/00
CPC分类号： H04W72/121 , H04W72/1231 , H04W72/1242
摘要： Various schedulers are disclosed for use within a network node of a radio access network. A scheduler can be configured to divide a defined frequency bandwidth into a plurality of bandwidth pipes. The scheduler then develops sets of nodes that are candidates for using corresponding ones of the bandwidth pipes to communicate with the network node during a communication time interval. At least one of the sets contains a plurality of candidate nodes. The scheduler operates separate parallel processes that are arranged for computing metrics for the sets of nodes. The scheduler assigns one of the nodes in each set of nodes to the corresponding bandwidth pipe in response to the computed metrics. The scheduler may divide the defined frequency bandwidth into a plurality of non-overlapping bandwidth pipes so that metrics for candidate nodes in one of the sets can be computed independently from candidate nodes in another one of the sets.
摘要翻译：公开了在无线电接入网络的网络节点内使用的各种调度器。调度器可以被配置为将定义的频率带宽划分成多个带宽管道。然后，调度器开发出在通信时间间隔期间使用对应的带宽管道与网络节点进行通信的候选者的节点集合。至少一个集合包含多个候选节点。调度器操作单独的并行进程，其被布置用于计算节点集合的度量。调度器响应于所计算的度量，将每组节点中的节点之一分配给相应的带宽管道。调度器可以将定义的频率带宽划分为多个不重叠的带宽管道，使得可以独立于另一组中的候选节点来计算其中一个集合中的候选节点的度量。

63. 发明授权

US08124584B2 Macrocyclic hepatitis C serine protease inhibitors 有权
标题翻译：大环丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US08124584B2
公开(公告)日：2012-02-28
申请号：US12351144
申请日：2009-01-09
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat Sun Or , Zhe Wang
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00
CPC分类号： C07D487/04 , A61K38/12 , C07K5/0806 , E05F15/73 , E05F2015/763
摘要： The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及式I，II或III的化合物或其药学上可接受的盐，酯或前药：其中W是取代或未取代的杂环体系。该化合物抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

64. 发明申请

US20120044880A1 Network Driven L3 Control Signalling Prioritization 有权
标题翻译：网络驱动L3控制信令优先级
公开(公告)号：US20120044880A1
公开(公告)日：2012-02-23
申请号：US12935025
申请日：2008-03-28
申请人： Ying Sun , Christian Skärby , Gunnar Peters , Kelvin Maliti , Krister Norlund
发明人： Ying Sun , Christian Skärby , Gunnar Peters , Kelvin Maliti , Krister Norlund
IPC分类号： H04W74/04
CPC分类号： H04W72/1242 , H04W72/1289
摘要： A node of a radio access network includes a transceiver and a radio resource control unit. The transceiver is configured to facilitate communication with plural wireless terminals over a radio interface including transmissions on an uplink from the wireless terminals to the node and transmissions on a downlink from the node to the wireless terminals.The radio resource control unit configured to perform radio resource control functionality including layer three (L3) signaling between the node and the wireless terminals. The radio resource control unit includes an uplink scheduler configured to predict transmission of an uplink L3 message from the wireless terminals to the node and, for a particular wireless terminal, to generate, for transmission on the downlink, a grant message which in accordance with the prediction prioritizes a predicted L3 message of the particular wireless terminal relative to messages of others of the plural wireless terminals.
摘要翻译：无线电接入网络的节点包括收发机和无线电资源控制单元。收发器被配置为促进通过无线电接口与多个无线终端的通信，包括在从无线终端到节点的上行链路上的传输和在从节点到无线终端的下行链路上的传输。所述无线资源控制部被配置为执行包括所述节点与所述无线终端之间的第三层（L3）信令的无线资源控制功能。无线电资源控制单元包括上行链路调度器，被配置为预测来自无线终端的上行链路L3消息的传输到节点，并且对于特定的无线终端，为了在下行链路上的传输而生成根据预测将特定无线终端的预测L3消息相对于多个无线终端中的其他消息的优先级排序。

65. 发明申请

US20120021014A1 CORROSION CURRENT-GENERATING METAL PARTICULATES AND USE THEREOF 审中-公开
标题翻译：腐蚀电流产生金属颗粒及其用途
公开(公告)号：US20120021014A1
公开(公告)日：2012-01-26
申请号：US13186816
申请日：2011-07-20
申请人： Jeannette Chantalat , Jeffrey C. Geesin , James E. Hauschild , Julia Hwang , Wei Kong , Jue-Chen Liu , William R. Parrish , Michael D. Southall , Brooks Story , Ying Sun , Chunlin Yang
发明人： Jeannette Chantalat , Jeffrey C. Geesin , James E. Hauschild , Julia Hwang , Wei Kong , Jue-Chen Liu , William R. Parrish , Michael D. Southall , Brooks Story , Ying Sun , Chunlin Yang
IPC分类号： A61K9/14 , A61K33/06 , A61K33/34 , A61K33/32 , A61P29/00 , A61P17/10 , A61P17/06 , A61P31/00 , A61P41/00 , A61K33/30 , A61P17/00
CPC分类号： A61K33/38 , A61K8/042 , A61K8/19 , A61K8/27 , A61K33/30 , A61K33/34 , A61K45/06 , A61K2800/412 , A61K2800/413 , A61K2800/83 , A61Q19/08 , A61K2300/00
摘要： Metal particulates capable of generating low levels of corrosion current beneficial for pharmaceutical, cosmetic and other medical uses are provided.
摘要翻译：提供能够产生有益于药物，化妆品和其它医疗用途的低水平腐蚀电流的金属微粒。

66. 发明申请

US20110236491A1 TOPICAL ANTI-INFLAMMATORY COMPOSITION 审中-公开
标题翻译：局部抗炎组合物
公开(公告)号：US20110236491A1
公开(公告)日：2011-09-29
申请号：US12842661
申请日：2010-07-23
申请人： Jeannette Chantalat , Jue-Chen Liu , May Shana'a , Michael Southall , Ying Sun
发明人： Jeannette Chantalat , Jue-Chen Liu , May Shana'a , Michael Southall , Ying Sun
IPC分类号： A61K38/43 , A61K9/14 , A61K33/30 , A61K33/34 , A61K33/38 , A61P29/00
CPC分类号： A61K45/06 , A61K8/0287 , A61K8/27 , A61K8/66 , A61K8/673 , A61K9/0014 , A61K33/30 , A61K33/34 , A61K33/38 , A61K38/44 , A61K38/443 , A61K41/0057 , A61K2800/412 , A61K2800/81 , A61N1/205 , A61Q19/08 , C12Y101/03004 , C12Y111/01006 , A61K2300/00
摘要： Compositions and methods for treating inflammation in mammalian tissue are provided using substantially continuously, in situ generated, anti-inflammatory effective amounts of hydrogen peroxide.
摘要翻译：使用基本上连续，原位产生的抗炎有效量的过氧化氢提供用于治疗哺乳动物组织中的炎症的组合物和方法。

67. 再颁专利

USRE42375E1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors 有权
标题翻译：喹喔啉基大环丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：USRE42375E1
公开(公告)日：2011-05-17
申请号：US12069553
申请日：2008-02-11
申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
发明人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Sun Or , Zhe Wang
IPC分类号： C07D401/12 , C07D409/14 , A61K31/38 , A61K31/395 , A61P31/12
CPC分类号： C07K5/0802 , A61K38/212 , A61K38/215 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

68. 发明申请

US20100268335A1 MEDICAL DEVICES WITH GALVANIC PARTICULATES 审中-公开
公开(公告)号：US20100268335A1
公开(公告)日：2010-10-21
申请号：US12761601
申请日：2010-04-16
申请人： Chunlin Yang , Ying Sun , Frank R. Cichocki, JR. , Saumen N. Bar , James E. Hauschild , Uri Herzberg , Yufu Li , Xintian Ming , Wei Kong , Jeannette Chantalat , Michael Southall
发明人： Chunlin Yang , Ying Sun , Frank R. Cichocki, JR. , Saumen N. Bar , James E. Hauschild , Uri Herzberg , Yufu Li , Xintian Ming , Wei Kong , Jeannette Chantalat , Michael Southall
IPC分类号： A61F2/02 , H01B1/22 , B32B5/16 , A61F2/28 , B05D5/00
CPC分类号： A61L15/18 , A61B17/06066 , A61B17/06166 , A61B17/064 , A61B2017/00884 , A61B2017/00889 , A61L15/42 , A61L26/0004 , A61L26/0066 , A61L27/306 , A61L27/50 , A61L29/106 , A61L29/14 , A61L31/088 , A61L31/14 , A61L2300/404 , A61N1/205 , A61N1/303 , Y10T428/256 , Y10T428/2982
摘要： Implantable medical devices having galvanic particulates are disclosed. The particulates may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The devices may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, and tissue regeneration promoting.

69. 发明授权

US07816367B2 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders 有权
公开(公告)号：US07816367B2
公开(公告)日：2010-10-19
申请号：US10591214
申请日：2005-02-24
申请人： Michelle Akerman , Jonathan Houze , Daniel C. H. Lin , Jiwen Liu , Jian Luo , Julio C. Medina , Wei Qiu , Jeffrey D. Reagan , Rajiv Sharma , Stephen J. Shuttleworth , Ying Sun , Jian Zhang , Liusheng Zhu , Jinqian Liu , Zhihua Ma , Yingcai Wang , Michael J. Schmitt
发明人： Michelle Akerman , Jonathan Houze , Daniel C. H. Lin , Jiwen Liu , Jian Luo , Julio C. Medina , Wei Qiu , Jeffrey D. Reagan , Rajiv Sharma , Stephen J. Shuttleworth , Ying Sun , Jian Zhang , Liusheng Zhu , Jinqian Liu , Zhihua Ma , Yingcai Wang , Michael J. Schmitt
IPC分类号： A61K31/44 , C07D213/02
CPC分类号： C07D277/24 , C07D277/30
摘要： The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula Q-L1-P-L2-M-X-L3-A wherein the definitions of the variables Q, L1, P, L2, M, X, L3 and A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.

70. 发明授权

US07728148B2 Acyclic oximyl hepatitis C protease inhibitors 失效
标题翻译：非环氧乙酰丙型肝炎蛋白酶抑制剂
公开(公告)号：US07728148B2
公开(公告)日：2010-06-01
申请号：US11758901
申请日：2007-06-06
申请人： Ying Sun , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Yat Sun Or , Zhe Wang
IPC分类号： C07D207/00 , C07D295/00
CPC分类号： C07D207/12 , A61K38/00 , C07D207/16 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/04 , C07K5/0812
摘要： The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式